Great question. I haven't seen banner ads on OpenEvidence yet, but the 'hidden tax' of free tools is often Publisher Bias.
Users have noted that some current tools heavily overweight citations from 'Partner Journals' (like NEJM/JAMA) because they index the full text, effectively burying better papers from non-partner journals in the vector retrieval.
My goal is strictly Neutral Retrieval. By hitting the PubMed/OpenAlex APIs live, Evidex treats a niche pediatric journal with the same relevance weight as a major publisher, ensuring the 'Long Tail' of evidence isn't drowned out by business partnerships.
amber_raza|2 months ago
Users have noted that some current tools heavily overweight citations from 'Partner Journals' (like NEJM/JAMA) because they index the full text, effectively burying better papers from non-partner journals in the vector retrieval.
My goal is strictly Neutral Retrieval. By hitting the PubMed/OpenAlex APIs live, Evidex treats a niche pediatric journal with the same relevance weight as a major publisher, ensuring the 'Long Tail' of evidence isn't drowned out by business partnerships.
breadislove|2 months ago
> $150M RR on just ads, +3x from August. On <1M users.
source: https://x.com/ArfurRock/status/1999618200024076620
amber_raza|2 months ago
Thanks for sharing that source. It really validates the thesis that unless the user pays (SaaS), the Pharma companies are the real customers.